Localization of Oncogenic Osteomalacia by Systemic Venous Sampling of Fibroblast Growth Factor 23
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Tumor-induced osteomalacia (TIO) is characterized by hypophosphatemia caused by a phosphaturic mesenchymal tumor. While surgical resection of the tumor leads to a cure, identification of the responsible tumor is challenging. Recently, several studies showed that systemic sampling of fibroblast growth factor 23 (FGF23) is helpful for localization of tumors. The present study aimed to evaluate the clinical utility of this method in Korean patients. Materials and Methods: Six patients compatible with TIO who were admitted to our hospital between 2006 and 2015 were analyzed. Systemic venous sampling of FGF23 was performed to detect blind lesions or to confirm a suspicious lesion identified in previous imaging studies. Results: Venous sampling helped confirming the tumor in five of the six patients. Three patients underwent surgery after sampling,and in two patients, the lesions were detected after 3 years by means of 68Ga-DOTATOC positron emission tomography with computed tomography. In one patient, there was a local elevation of serum FGF23 without any related lesion on additional imaging. Conclusion: Our data strengthened the value of venous sampling of FGF23 in predicting the location of tumors and suggested that it can be more effective in the presence of the relevant lesion in subsequent imaging analyses.
Abstract
Purpose: Tumor-induced osteomalacia (TIO) is characterized by hypophosphatemia caused by a phosphaturic mesenchymal tumor. While surgical resection of the tumor leads to a cure, identification of the responsible tumor is challenging. Recently, several studies showed that systemic sampling of fibroblast growth factor 23 (FGF23) is helpful for localization of tumors. The present study aimed to evaluate the clinical utility of this method in Korean patients. Materials and Methods: Six patients compatible with TIO who were admitted to our hospital between 2006 and 2015 were analyzed. Systemic venous sampling of FGF23 was performed to detect blind lesions or to confirm a suspicious lesion identified in previous imaging studies. Results: Venous sampling helped confirming the tumor in five of the six patients. Three patients underwent surgery after sampling,and in two patients, the lesions were detected after 3 years by means of 68Ga-DOTATOC positron emission tomography with computed tomography. In one patient, there was a local elevation of serum FGF23 without any related lesion on additional imaging. Conclusion: Our data strengthened the value of venous sampling of FGF23 in predicting the location of tumors and suggested that it can be more effective in the presence of the relevant lesion in subsequent imaging analyses.
참고문헌 (27)
- Chong WH, "Tumor-induced osteomalacia", Endocr Relat Cancer, 18, pp.R53~R77 (2011)
- Hautmann AH, "Tumorinduced osteomalacia: an up-to-date review", Curr Rheumatol Rep, 17, pp.512~ (2015)
- Seiji Fukumoto, "Diagnostic Modalities for FGF23-Producing Tumors in Patients with Tumor-Induced Osteomalacia", Endocrinology and Metabolism, 29(2), pp.136~143 (2014), 대한내분비학회
- Shimada T, "FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa", Biochem Biophys Res Commun, 314, pp.409~414 (2004)
- Ito N, "Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia", J Intern Med, 268, pp.390~394 (2010)
- Takeuchi Y, "Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia", J Clin Endocrinol Metab, 89, pp.3979~3982 (2004)
- Nasu T, "Tumor-induced hypophosphatemic osteomalacia diagnosed by the combinatory procedures of magnetic resonance imaging and venous sampling for FGF23", Intern Med, 47, pp.957~961 (2008)
- van Boekel G, "Tumor producing fibroblast growth factor 23localized by two-staged venous sampling", Eur J Endocrinol, 158, pp.431~437 (2008)
- Westerberg PA, "Preoperative tumor localization by means of venous sampling for fibroblast growth factor-23 in a patient with tumor-induced osteomalacia", Endocr Pract, 14, pp.362~367 (2008)
- Andreopoulou P, "Cutler Peck CM, Wodajo FM, et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors", J Bone Miner Res, 26, pp.1295~1302 (2011)
- Folpe AL, "Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature", Am J Surg Pathol, 28, pp.1~30 (2004)
- McCance RA, "Osteomalacia with Looser’s nodes (Milkman’s syndrome)due to a raised resistance to vitamin D acquired about the age of 15 years", Q J Med, 16, pp.33~46 (1947)
- Prader A, "Rickets following bone tumor", Helv Paediatr Acta, 14, pp.554~565 (1959)
- Jan de Beur SM, "Tumor-induced osteomalacia", JAMA, 294, pp.1260~1267 (2005)
- Jan de Beur SM, "Localisation of mesenchymal tumours by somatostatin receptor imaging", Lancet, 359, pp.761~763 (2002)
- Park YK, "Oncogenic osteomalacia", Korean J Pathol, 40, pp.1~8 (2006)
- Reubi JC, "Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors:in vitro identification", Cancer Res, 56, pp.1922~1931 (1996)
- Jiang Y, "Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature", J Bone Miner Res, 27, pp.1967~1975 (2012)
- Dupond JL, "Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET", CT scan for the diagnosis and follow-up in one case, 2005, pp.36, 375~378
- Jagtap VS, "Tumor-induced osteomalacia: a single center experience", Endocr Pract, 17, pp.177~184 (2011)
- Agrawal K, "Comparison of 18F-FDG and 68Ga DOTATATE PET", CT in localization of tumor causing oncogenic osteomalacia, 2015, pp.40, e6~e10
- Shimada T, "Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia", Proc Natl Acad Sci U S A, 98, pp.6500~6505 (2001)
- Schiavi SC, "The phosphatonin pathway: new insights in phosphate homeostasis", Kidney Int, 65, pp.1~14 (2004)
- Jonsson KB, "Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia", N Engl J Med, 348, pp.1656~1663 (2003)
- Clifton-Bligh RJ, "Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET", CT, 2013, pp.98, 687~694
- Breer S, "68Ga DOTA-TATE PET", CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT, Bone, pp.2014, 64[DOI]
- Antunes P, "Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?", Eur J Nucl Med Mol Imaging, 34, pp.982~993 (2007)